Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use

Volume: 23, Issue: 1
Published: Jul 17, 2021
Abstract
The Oncotype DX breast recurrence score has been introduced more than a decade ago to aid physicians in determining the need for systemic adjuvant chemotherapy in patients with early-stage, estrogen receptor (ER)+, lymph node-negative breast cancer.In this study, we utilized data from The Surveillance, Epidemiology, and End Results (SEER) Program to investigate temporal trends in Oncotype DX usage among US breast cancer patients in the first...
Paper Details
Title
Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
Published Date
Jul 17, 2021
Volume
23
Issue
1
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.